Fact CheckerSign in

NCT07077798Not yet recruiting

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection: A Multicenter Prospective Study

Source: ClinicalTrials.gov · Last updated 22 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Vessels that encapsulate tumor clusters (VETC) are a novel invasive metastatic factor in hepatocellular carcinoma (HCC), operating independently of the epithelial-mesenchyme transition (EMT). The presence of VETC is associated with a higher rate of postoperative recurrence in HCC patients, indicating a more aggressive biological behavior.Improving the prognosis for VETC-positive patients is a critical issue in clinical oncology.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
234 (estimated)
First submitted
11 Jul 2025
Start date
1 Aug 2025
Primary completion date
31 Aug 2026
Lead sponsor
Wan-Guang Zhang
NCT number
NCT07077798

What you commit to

  • Study type: Interventional
  • Planned participants: 234
  • From 1 Aug 2025 to the primary completion date, 31 Aug 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Lab values

  • Pregnant or breastfeeding women;
    • Recurrent HCC, distant metastasis or other systemic tumors;
    • Vascular invasion involving the mesenteric vein, main portal vein, hepatic vein or inferior vena cava;
    • History of gastrointestinal bleeding within the past 4 weeks;
    • Active infection; ⑥Other significant clinical and laboratory abnormalities that affect safety evaluation; ⑦Inability to follow the study protocol, receive treatment or follow-up as scheduled

Who the study is looking for

  • Age 18-75 years;
    • No previous local or systemic treatment for hepatocellular carcinoma;
    • Child-Pugh liver function score ≤ 7; ④ECOG PS 0-1; ⑤BCLC stage 0-C, underwent R0 resection and confirmed by pathology as hepatocellular carcinoma; ⑥No major systemic diseases, immunodeficiency diseases, etc.; ⑦CD34 immunohistochemical staining confirms the presence of VETC in the intratumoral vascular pattern (part or all of the field of view)

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.